Ascentage Pharma Group International (AAPG) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Ascentage Pharma Group International (AAPG) Earnings Overview
As of June 29, 2026, Ascentage Pharma Group International (AAPG) reported trailing twelve-month net income of -$1.64B, reflecting -153.0% year-over-year growth. The company earned $-17.67 per diluted share over the past four quarters, with a net profit margin of -216.5%.
Looking at the long-term picture, AAPG's historical earnings data spans multiple years. The company achieved its highest annual net income of -$108M in fiscal 2016.
Ascentage Pharma Group International is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ABBV ($3.64B net income, 6.9% margin), BCAB (-$51M net income, -2980.3% margin), KYMR (-$315M net income, -794.4% margin), AAPG has room to improve margins relative to the peer group. Compare AAPG vs ABBV →
AAPG Earnings vs Peers
Earnings metrics vs comparable public companies
AAPG Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$1.21B | -198.2% | -$1.18B | $-13.56 | -216.5% | -211.1% |
| 2024 | -$405M | +56.2% | -$370M | $-5.36 | -41.3% | -37.7% |
| 2023 | -$926M | -4.8% | -$873M | $-52.48 | -417.0% | -393.1% |
| 2022 | -$883M | -12.8% | -$850M | $-53.60 | -421.0% | -405.2% |
| 2021 | -$782M | -15.5% | -$870M | $-49.12 | -2803.4% | -3116.6% |
| 2020 | -$678M | +54.2% | -$664M | $-50.24 | -5442.6% | -5332.9% |
| 2019 | -$1.48B | -328.8% | -$583M | $-112.04 | -10202.7% | -4014.9% |
| 2018 | -$345M | -191.4% | -$345M | $-26.68 | -5072.8% | -5074.8% |
| 2017 | -$119M | -9.9% | -$131M | $-9.16 | -1872.9% | -2064.9% |
| 2016 | -$108M | - | -$115M | $-8.32 | -1406.5% | -1495.0% |
Download Data
Export AAPG earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AAPG — Frequently Asked Questions
Quick answers to the most common questions about buying AAPG stock.
What is AAPG earnings per share (EPS)?
AAPG trailing twelve-month (TTM) diluted EPS is $-17.67, reflecting -153.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Ascentage Pharma Group International's net income?
Ascentage Pharma Group International (AAPG) trailing twelve-month net income is $-1.6B as of 2025. Earnings declined -153.0% year-over-year.
Is AAPG profitable?
AAPG is not currently profitable on a TTM basis, reporting a net loss of $-1.6B. Net margin is -216.5%. Investors should monitor for a return to profitability.
What is AAPG's earnings growth rate?
AAPG compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are AAPG's profit margins?
Ascentage Pharma Group International net profit margin is -216.5%, operating margin is -211.1%, and gross margin is +76.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -150.2%.
Is AAPG growing earnings?
AAPG earnings are declining — EPS fell -153.0% year-over-year. TTM net income dropped to $-1.6B. This contrasts with the 5-year CAGR of N/A.
What was AAPG's best earnings year?
Ascentage Pharma Group International's highest annual net income on record is $-108M, achieved in fiscal year 2016. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were AAPG's earnings last quarter?
AAPG's most recent reported quarter was Q4 2025. Net income was $-640M with diluted EPS of $-6.92. For a full breakdown of all quarters, see the quarterly earnings table on this page.